Compare Abeona Therapeutics Inc (ABEO) vs CVS Health Corp (CVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs CVS Health Corp — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while CVS Health Corp trades at $104.9 (market cap $133.12B). The key difference: CVS Health Corp is far larger — about 356.6× Abeona Therapeutics Inc's market cap, and CVS Health Corp pays a 2.55% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CVS | |
|---|---|---|
Market Cap | $373.32M | $133.12B |
Sector | Health | Health |
52-Week High | $7.23 | $104.81 |
52-Week Low | $4.17 | $58.75 |
Enterprise Value | $228.22M | $199.66B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CVS Health trades at $104.33, down slightly on the day, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates, including a recent Q1 2026 beat, and benefits from positive sentiment around strategic initiatives like GLP-1 drug access. Revenue growth remains solid, though net margins are thin. The current price sits just below the consensus price target of $106.86.
The outlook for CVS is positive, driven by earnings momentum and strategic positioning in healthcare services. Key opportunities include margin expansion potential and market share gains. Risks involve intense competition, regulatory pressures on healthcare pricing, and the company's significant debt load, which requires careful management of cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
